Show simple item record

AuthorIbrahim, Mohamed Izham Mohamed
AuthorAwaisu, Ahmed.
Available date2022-04-10T10:25:32Z
Publication Date2020
Publication NameGlobal Pharmaceutical Policy
ResourceScopus
Identifierhttp://dx.doi.org/10.1007/978-981-15-2724-1_3
URIhttp://hdl.handle.net/10576/29401
AbstractPatient access to safe and cost-effective treatment is an important goal for the healthcare system. The development of biosimilar compounds and generic medicines is interesting to the industry and society to reduce healthcare costs, fulfill the needs of healthcare stakeholders and potentially increase accessibility to patients. Patient and physician acceptance, with many patients preferring biologics and branded products and physicians prescribing the same, limits the use of generic medicine and biosimilars. The growth of these products in part depends on various stakeholders' decisions to provide, pay for or use these products in a safe and thoughtful manner. Ongoing stakeholder collaboration, educational activities and review of current government and payer policies are required to optimize the uptake of generic medicines and biosimilars.
Languageen
PublisherPalgrave Macmillan
SubjectGeneric medicines
biosimilars
pharmaceutical policy
TitleGeneric medicines and biosimilars: Impact on global pharmaceutical policy
TypeBook chapter
Pagination53-72
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record